[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":286},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,46,76,109,137,162,193,216,241,261],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100646052","network-guided-theta-burst-stimulation-for-breast-cancer-with-chemotherapy-induced-peripheral-neuropathy-clinical-and-fmri-biomarker-evidence-100646052",false,"NCT07695415","Network-Guided Theta Burst Stimulation for Breast Cancer With Chemotherapy-Induced Peripheral Neuropathy: Clinical and fMRI Biomarker Evidence","CIPN TBS","Inclusion Criteria:\n\n* a. breast cancer patients aged between ２０- and 80-years-old with CIPN b. history of receiving chemotherapy including taxane-based neurotoxic agents c. with neuropathic pain, score≥3 in a 0-10 VAS pain scale. d. with fair cognition and can cooperate to evaluate pain severity. e. neither at end-stage cancer nor at the estimated survival time less than 6 months.\n\nExclusion Criteria:\n\n* a. brain tumor or history of epilepsy b. intracranial metallic devices, artificial cochleae, pacemakers, or any other metal device c. recent myocardial ischemia or unstable angina d. severe cognitive dysfunction or pregnancy e. injuries or fractures in the part of neuropathic pain","FEMALE","20 Years","85 Years",{"count":20,"type":21},40,"ESTIMATED","INTERVENTIONAL",[24],"NA","Chemotherapy-induced peripheral neuropathy (CIPN) is a common and debilitating complication among breast cancer survivors, frequently associated with chronic neuropathic pain that remains inadequately controlled by pharmacological treatments. Emerging evidence suggests that CIPN pain is related to maladaptive reorganization of pain-related brain networks, highlighting the potential of non-pharmacological, brain-based neuromodulation strategies.\n\nAmong the variants of theta burst stimulation (TBS), both prolonged constant theta burst stimulation (pcTBS) and intermittent theta burst stimulation (iTBS) have facilitating effects of cortical excitability. The treatment time for pcTBS (1 min and 44 s, 1200 pulses) is much shorter than that of iTBS and traditional repetitive transcranial magnetic stimulation (rTMS); therefore, pcTBS seems to be a promising neuromodulation method for chronic pain and head-to-head comparison between pcTBS and iTBS has never been done before.\n\nThe aim of this two-year randomized, cross-over trial project is 1) to compare the effects of pcTBS and iTBS and determine the optimal TBS paradigm for alleviating CIPN pain a sequential focus on distinct cortical targets; 2) to implement a prospectively defined, network-guided framework using fMRI to characterize sensorimotor and pain-related brain connectivity and to examine whether baseline network features and stimulation-induced connectivity changes moderate clinical outcomes.\n\nIn Year 1, 20 breast cancer patients with CIPN will be recruited and randomly assigned to two groups: Group I will initially receive pcTBS over M1 for 5 consecutive days and then iTBS over M1 after a 8-week \"wash-out\" period. Group II will initially receive iTBS over M1 for 5 consecutive days and then pcTBS over M1 after a 8-week \"wash-out\" period. In year 2, the stimulation target will be changed to dorsolateral prefrontal cortex (DLPFC) to evaluate analgesic effects, and associated brain network changes related to cognitive-affective pain modulation.\n\nMRI-based neuronavigation will be used to ensure precise and reproducible stimulation targeting. Both resting-state and task-based functional MRI will be acquired before stimulation and used prospectively to identify individualized pain-relevant cortical hotspots within predefined anatomical regions (M1 or DLPFC). Resting-state fMRI will be repeated within 24 hours after the final stimulation session to evaluate treatment-related changes in brain networks. Pain intensity measured by the visual analog scale will serve as the primary outcome, with secondary outcomes including Neuropathic Pain Symptom Inventory, Depression Anxiety Stress Scale 21 and pressure pain threshold testing. Primary and secondary outcomes will be evaluated immediately after the last stimulation session and again at 4-week follow-up.\n\nBy integrating a clinically efficient trial design with network-informed neuroimaging, this project is expected to provide target-specific evidence for TBS in CIPN pain and to establish a foundation for future precision-guided neuromodulation studies.",[27,28],"CIPN - Chemotherapy-Induced Peripheral Neuropathy","Breast Cancer",[30,31,32],"CIPN","breast cancer","theta burst stimulation","NOT_YET_RECRUITING","2026-07-06",{"date":36,"type":37},"2026-07-10","ACTUAL",{"date":39,"type":21},"2026-08-01",{"date":41,"type":21},"2029-12-31",{"name":43,"class":44},"Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":53,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":45},"100616837","phase-4-comparison-of-mirabegron-and-tamsulosin-for-ureteral-stone-expulsion-100616837","NCT07310797","Comparison of Mirabegron and Tamsulosin for Ureteral Stone Expulsion","A Randomized Controlled Trial Comparing Mirabegron and Tamsulosin for Ureteral Stone Expulsion and Clinical Symptom Improvement","Inclusion Criteria:\n\n1. Age and Sex: Adult patients aged 18 to 75 years, inclusive of both males and females.\n2. Diagnosis: Unilateral ureteral stone confirmed by Computed Tomography (CT), Renal Sonography, or Kidney-Ureter-Bladder (KUB) radiography.\n3. Stone Characteristics: Stone size between 4 mm and 10 mm; located in the upper (proximal), middle, or lower (distal) ureter.\n4. Symptoms and Renal Function: Presence of renal colic or hematuria, with no severe renal insufficiency (eGFR \\> 60 mL\u002Fmin\u002F1.73m²).\n\nExclusion Criteria:\n\n1. Urinary tract infection (UTI).\n2. Multiple or bilateral ureteral stones.\n3. Ureteral stones not visible on KUB radiography (radiolucent stones).\n4. Pregnant or lactating women.\n5. Severe hydronephrosis.\n6. Renal insufficiency (defined as eGFR \\\u003C 30 mL\u002Fmin\u002F1.73m² or Serum Creatinine \\> 2 mg\u002FdL).\n7. Uncontrolled hypertension or major cardiovascular disease.\n8. Patients who refuse Medical Expulsive Therapy (MET).","ALL","18 Years","75 Years",{"count":57,"type":21},500,[59],"PHASE4","This randomized controlled trial compares the efficacy and safety of four treatment strategies for ureteral stone expulsion: Mirabegron alone, Tamsulosin alone, a combination of both, and standard conservative care. Participants diagnosed with ureteral stones will be randomly assigned to one of these four groups. The primary objective is to evaluate the stone expulsion rate within 4 weeks. The study also assesses time to expulsion, pain intensity, analgesic use, and potential side effects.",[62],"Ureteral Calculi",[64,65,66],"Mirabegron","Tamsulosin","Medical Expulsive Therapy","RECRUITING","2026-06-04",{"date":70,"type":37},"2026-06-08",{"date":72,"type":37},"2026-02-13",{"date":74,"type":21},"2030-12-31",{"name":43,"class":44},{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":83,"targetDuration":85,"studyType":86,"phases":4,"briefSummary":87,"conditions":88,"keywords":94,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":45},"100629294","longitudinal-body-composition-assessment-in-breast-cancer-patients-100629294","NCT07472803","Longitudinal Body Composition Assessment in Breast Cancer Patients","Long-term Evaluation of the Body Composition and the Impact of Resistance and Relaxation Exercise on Muscle Mass and Quality of Life in Patients With Breast Cancer","Inclusion Criteria:\n\n* \\>18 years of age\n* Diagnosed with stage I-III non-metastatic breast cancer within 12 months of diagnosis\n* Scheduled for surgery, chemotherapy, with or without radiotherapy or targeted therapy.\n\nExclusion Criteria:\n\n* Women diagnosed with metastatic (stage IV) breast cancer\n* Women planning to move away from the area or be away for more than 6 months during the study period\n* Women planning to become pregnant during the study period\n* Implantable devices (e.g., pacemaker, nerve stimulator) or surgical implants (e.g., total hip or knee replacements)",{"count":84,"type":21},100,"12 Months","OBSERVATIONAL","This observational cohort study aims to track longitudinal changes in body composition, including skeletal muscle mass and fat distribution, in patients diagnosed with breast cancer. Following primary surgery and adjuvant therapy, participants will be monitored over a 2-year period.\n\nThe primary objective is to evaluate the natural progression of skeletal muscle mass index (SMI) and metabolic changes in this population. By conducting serial measurements, this study seeks to characterize the longitudinal trends in muscle loss and body composition shifts post-treatment, providing data to better understand the physiological impact of the cancer recovery process.",[89,90,91,92,93],"Breast Neoplasms","Body Composition","Sarcopenia","Fat Redistribution","Lymphedema",[95,96,90,97,98,99,100],"Breast Cancer Survivors","Post-Treatment Recovery","Longitudinal Cohort Study","Skeletal Muscle Mass Index","Metabolic Monitoring","sarcopenia","2026-03-12",{"date":103,"type":37},"2026-03-16",{"date":105,"type":37},"2025-05-19",{"date":107,"type":21},"2027-12-31",{"name":43,"class":44},{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":115,"eligibilityCriteria":116,"healthyVolunteers":11,"sex":117,"minAge":54,"maxAge":118,"enrollmentInfo":119,"targetDuration":4,"studyType":22,"phases":121,"briefSummary":122,"conditions":123,"keywords":125,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":136,"locationsCount":45},"100620401","jing-si-herbal-tea-as-adjuvant-treatment-in-patients-with-chronic-pelvic-pain-syndrome-100620401","NCT07357142","Jing Si Herbal Tea as Adjuvant Treatment in Patients With Chronic Pelvic Pain Syndrome","JING SI HERBAL TEA Use as Adjuvant Treatment in Patients With Chronic Pelvic Pain Syndrome","JSHT-CPPS","Inclusion Criteria:\n\n1. Male patients.\n2. Diagnosed with Chronic Pelvic Pain Syndrome (CPPS) at the investigational site.\n3. Currently receiving continuous follow-up and medical treatment.\n\nExclusion Criteria:\n\n1. Female patients (Excluded because the standard treatment, alpha-blockers, is not approved or reimbursed by the National Health Insurance for this indication in women in Taiwan).\n2. Duration of symptoms less than 3 months.\n3. History of recurrent urinary tract infections.\n4. Diagnosed with malignancy.\n5. Hospitalization for other diseases within the past 3 months.\n6. Unwilling to participate in the study.","MALE","100 Years",{"count":120,"type":21},400,[24],"The purpose of this clinical trial is to evaluate the efficacy of Jing Si Herbal Tea as an adjuvant treatment for patients diagnosed with Chronic Pelvic Pain Syndrome (CPPS). The study aims to determine whether adding Jing Si Herbal Tea to standard care can improve clinical symptoms and quality of life in these patients.",[124],"Chronic Pelvic Pain Syndrome (CPPS)",[126,127,128,129],"Chronic Pelvic Pain Syndrome","CPPS","Jing Si Herbal Tea","Herbal Medicine","2026-02-02",{"date":132,"type":37},"2026-02-04",{"date":134,"type":21},"2026-03-01",{"date":74,"type":21},{"name":43,"class":44},{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":143,"eligibilityCriteria":144,"healthyVolunteers":11,"sex":53,"minAge":145,"maxAge":118,"enrollmentInfo":146,"targetDuration":4,"studyType":22,"phases":148,"briefSummary":149,"conditions":150,"keywords":152,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":45},"100607215","the-effect-of-walking-exercise-in-patients-with-chronic-obstructive-pulmonary-disease-100607215","NCT07185659","The Effect of Walking Exercise in Patients With Chronic Obstructive Pulmonary Disease","The Effect of Walking Exercise on Anxiety, Depression, Dyspnea, Life and Sleep Quality in Patients With Chronic Obstructive Pulmonary Disease.","COPD","Participants were recruited according to the following criteria.\n\nInclusion Criteria:\n\n* Inpatients diagnosed with chronic obstructive pulmonary disease (COPD) according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria.\n* Age ≥ 40 years.\n* Post-bronchodilator FEV₁\u002FFVC ratio \\\u003C 70%.\n* History of smoking.\n* Ability to perform walking exercises.\n* Willingness of the patient or a family member to provide written informed consent.\n\nExclusion Criteria:\n\n* Panic disorder.\n* Presence of delirium with inability to cooperate.\n* Currently receiving cancer treatment.\n* Angina pectoris or myocardial infarction within the past 3 months.\n* Currently undergoing high-intensity rehabilitation exercises.","40 Years",{"count":147,"type":21},68,[24],"\"Patients were divided into two groups: the experimental group (E group) and the control group (C group). The E group received standard care, walking exercise, and elastic band exercise, and wore a smart bracelet to record walking steps and sleep for three months. During the first month, participants performed walking exercise for 100 minutes per week and used a red elastic band for resistance training. In the second month, walking exercise increased to 150 minutes per week with a green elastic band. In the third month, walking exercise increased to 150-300 minutes per week with a blue elastic band. The C group wore the smart bracelet to record walking steps and sleep for three months. Each group included 34 participants. The study was conducted from September 9, 2021, to December 31, 2025. Exclusion criteria included panic disorder, cognitive impairment, current cancer treatment, angina pectoris or myocardial infarction within the past 3 months, participation in high-intensity rehabilitation exercise, and walking dysfunction. Participants were required to follow the study protocol.\n\n* Assessments\\*\\*:\n* Anxiety and Depression\\*\\*:Measured using the Chinese version of the Hospital Anxiety and Depression Scale (HADS).\n* Dyspnea\\*\\*:Measured using the Modified Medical Research Council (mMRC) scale.\n* Life and Sleep quality\\*\\*:Measured using the COPD Assessment Test (CAT) and Chinese Version of the Pittsburgh Sleep Quality Index (CPSQI).",[151],"Chronic Obstructive Pulmonary Disease (COPD)",[153],"Chronic obstructive pulmonary disease","2025-09-18",{"date":156,"type":37},"2025-09-22",{"date":158,"type":37},"2021-09-09",{"date":160,"type":21},"2025-12-31",{"name":43,"class":44},{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":4,"eligibilityCriteria":168,"healthyVolunteers":169,"sex":53,"minAge":54,"maxAge":170,"enrollmentInfo":171,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":173,"conditions":174,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":45},"100402865","liver-disease-and-other-systemic-diseases-100402865","NCT04525833","Liver Disease and Other Systemic Diseases","The Association of Liver Disease With Other Systemic Diseases, Focus on Diseases Progression, Treatments, and Clinical Outcomes: Analyses From the Hospital Database of Buddhist Tzu Chi Medical Foundation","Inclusion Criteria:\n\n* Individuals who visited the gastroenterology clinics of the Tzu Chi Hospitals, Buddhist Tzu Chi Medical Foundation\n\nExclusion Criteria:\n\n* Age younger than 18 or older than 99 years",true,"99 Years",{"count":172,"type":21},15000,"Examine the association of chronic liver diseases (including hepatitis B, hepatitis C, alcoholic liver disease, fatty liver, liver cirrhosis, and hepatocellular carcinoma) with other systemic diseases by retrospectively analyzing the data from the Hospital Database of Buddhist Tzu Chi Medical Foundation.",[175,176,177,178,179,180,181,182,183,184],"Liver Diseases","Humans","Progression","Carcinogenesis","Fatty Liver Disease","Hepatitis C","Hepatitis B","Hepatocellular Carcinoma","Liver Cirrhoses","Treatment Outcome","2025-09-16",{"date":187,"type":37},"2025-09-19",{"date":189,"type":37},"2020-01-01",{"date":191,"type":21},"2026-12-31",{"name":43,"class":44},{"id":194,"slug":195,"hasResults":11,"nctId":196,"briefTitle":197,"officialTitle":198,"acronym":4,"eligibilityCriteria":199,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":200,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":202,"conditions":203,"keywords":204,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":210,"startDateStruct":212,"completionDateStruct":214,"leadSponsor":215,"locationsCount":45},"100600337","clinical-observational-studiesintegrative-tcm-and-western-medicine-for-breast-cancer-100600337","NCT07096180","Clinical Observational Studies:Integrative TCM and Western Medicine for Breast Cancer","Clinical Observational Studies: Breast Cancer Treatment by Traditional Chinese and Western Medicine","Inclusion Criteria:\n\n* A. Aged 18 years or above.\n* B. Female patients diagnosed with primary breast cancer and receiving Western medical treatment. The included breast cancer diagnosis codes based on ICD-9 are 174 to 179.\n\nExclusion Criteria:\n\n* A. Patients with a prior diagnosis of other malignant tumors before being diagnosed with primary breast cancer.\n* B. Patients with primary breast cancer who have not received Western medical treatment, meaning they have not undergone surgical resection, radiation therapy, chemotherapy, or targeted therapy..\n* C. After taking Chinese medicine, those who have uncomfortable symptoms or whose behavior affects Western medicine treatment should withdraw from the trial.",{"count":201,"type":21},200,"The aim of this study is to investigate the intervention of traditional Chinese medicine (TCM) in managing the side effects experienced by breast cancer patients undergoing conventional Western medical treatments, such as blood cell decline, nausea, vomiting, gastrointestinal discomfort, and overall quality of life. The study aims to establish a long-term clinical enrollment criteria and process for TCM adjuvant therapy in breast cancer. The research design will utilize a prospective cohort study and real-world cross-sectional observational research method to obtain clinical data and survival status of the patients.",[28],[205,206,207,208],"Traditional Chinese medicine","Adjunctive therapy","Side-Effect","Quality of Life","2025-07-30",{"date":211,"type":37},"2025-07-31",{"date":213,"type":37},"2024-01-01",{"date":191,"type":21},{"name":43,"class":44},{"id":217,"slug":218,"hasResults":11,"nctId":219,"briefTitle":220,"officialTitle":220,"acronym":4,"eligibilityCriteria":221,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":222,"enrollmentInfo":223,"targetDuration":4,"studyType":22,"phases":224,"briefSummary":225,"conditions":226,"keywords":228,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":234,"lastUpdatePostDateStruct":235,"startDateStruct":237,"completionDateStruct":239,"leadSponsor":240,"locationsCount":45},"100515936","clinical-efficacy-evaluation-of-electroacupuncture-as-adjuvant-therapy-for-female-patients-with-overactive-bladder-100515936","NCT05997992","Clinical Efficacy Evaluation of Electroacupuncture as Adjuvant Therapy for Female Patients With Overactive Bladder","Inclusion Criteria:\n\n* Female patient aged 20-80 with overactive bladder.\n\nExclusion Criteria:\n\n* Patient has history of cancer, stroke, or hyperthyroidism..\n* Patient isn't willing to accept acupuncture or moxibustion treatment.\n* Patient who is pregnant or plan to pregnant.\n* Patient with urinary tract infection.\n* Patient who had injection of botulinum toxin (Botox®), PTNS or SMN treatment before.\n* Patient recieved acupuncture treatment before.","80 Years",{"count":84,"type":21},[24],"Overactive bladder (OAB) is often accompanied by frequent urination and nocturia, and does not necessarily manifest as urge incontinence. Urgency to urinate and frequent urination can lead to psychological burdens, affect interpersonal relationships and reduce women's quality of life.\n\nTreatment of OAB includes lifestyle changes, behavioral therapy, drug therapy, neuromodulation, botulinum toxin therapy, and surgical intervention. At present, anticholinergic drugs are usually the first-line treatment for OAB, but the side effects of dry mouth often lead to poor patient compliance.\n\nTranscutaneous tibial nerve stimulation (PTNS) is a minimally invasive neuromodulation technique. Past studies have confirmed that PTNS has clinical efficacy in treating symptoms related to overactive bladder, while TCM's electroacupuncture is similar to PTNS. The main purpose of this study was to evaluate the specific acupoints in accordance with traditional Chinese medicine theory in women with OAB under conventional Western medicine treatment to evaluate the improvement of women's related urinary tract symptoms, quality of life and autonomic nervous system function.",[227],"Overactive Bladder",[229,230,231,232,233],"Urge Incontinence","Overactive bladder","quality of life","TCM constitution,","Electroacupuncture","2025-06-03",{"date":236,"type":37},"2025-06-05",{"date":238,"type":37},"2023-01-11",{"date":160,"type":21},{"name":43,"class":44},{"id":242,"slug":243,"hasResults":11,"nctId":244,"briefTitle":245,"officialTitle":245,"acronym":4,"eligibilityCriteria":246,"healthyVolunteers":11,"sex":53,"minAge":17,"maxAge":222,"enrollmentInfo":247,"targetDuration":4,"studyType":22,"phases":249,"briefSummary":250,"conditions":251,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":253,"lastUpdatePostDateStruct":254,"startDateStruct":256,"completionDateStruct":258,"leadSponsor":259,"locationsCount":260},"100477070","proximal--versus-distal-prioritized-robotic-practice-plus-kinetic-exergaming-in-stroke-rehabilitation-100477070","NCT05492175","Proximal- Versus Distal-Prioritized Robotic Practice Plus Kinetic Exergaming in Stroke Rehabilitation","Inclusion Criteria:\n\n1. a first ever-stroke≧3 months\n2. age range between 20 to 80 years\n3. baseline Fugl-Meyer assessment of upper extremity scale (FMA-UE) between 18 to 56\n4. no excessive muscle spasticity of the affected extremities (Modified Ashworth Scale \\\u003C 3 at any joints)\n5. able to follow examiners' commands and study instructions (Mini-Mental State Examination score≧22)\n6. can maintain a step-standing position for at least 30 seconds\n7. can walk for at least 10 meters with or without device\n8. no participation in further experimental rehabilitation or drug studies during the duration of the project\n\nExclusion Criteria:\n\n1. acute inflammation and pain\n2. concomitant neurologic, neuromuscular or orthopedic conditions that may impede participation in this research.",{"count":248,"type":21},72,[24],"This research program aims at investigating the effects of upper-limb robotic therapy primed with interactive exergaming as an innovative hybrid regimen in stroke rehabilitation.",[252],"Stroke Rehabilitation","2025-02-18",{"date":255,"type":37},"2025-02-19",{"date":257,"type":37},"2022-02-17",{"date":191,"type":21},{"name":43,"class":44},4,{"id":262,"slug":263,"hasResults":11,"nctId":264,"briefTitle":265,"officialTitle":266,"acronym":4,"eligibilityCriteria":267,"healthyVolunteers":11,"sex":53,"minAge":17,"maxAge":4,"enrollmentInfo":268,"targetDuration":4,"studyType":22,"phases":270,"briefSummary":272,"conditions":273,"keywords":275,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":278,"lastUpdatePostDateStruct":279,"startDateStruct":281,"completionDateStruct":283,"leadSponsor":285,"locationsCount":45},"100561025","early-phase-1-therapeutic-effects-of-jing-si-herbal-tea-for-copd-100561025","NCT06584786","Therapeutic Effects of Jing Si Herbal Tea for COPD","Therapeutic Effects of Jing Si Herbal Tea for Chronic Obstructive Pulmonary Disease: A Comprehensive Investigation From Clinical to Basic Research","Inclusion Criteria:\n\n* COPD patients willing to enter this study\n\nExclusion Criteria:\n\n* not COPD patients, no willing to enter this study",{"count":269,"type":21},120,[271],"EARLY_PHASE1","Chronic obstructive pulmonary disease (COPD), a leading cause of global mortality, significantly impairs health-related quality of life (HRQL). COPD is characterized by airway inflammation and lung tissue damage. Jing Si herbal tea (JSHT) is known to have anti-inflammatory effects but has not been explored for treating COPD. This study investigated the potential of JSHT as an adjuvant therapy for COPD. This randomized controlled study focused on patients with COPD in the exacerbation and stable phases. The control group received the standard treatment, and the JSHT group received the standard treatment plus JSHT. Both groups underwent HRQL assessments, blood tests, and cellular studies involving five different groups to assess the effect of JSHT on damage-associated molecular patterns (DAMPs) and inflammatory markers.",[274],"Airway Disease",[143,276,277],"Jing Si herbal tea","damage-associated molecular patterns","2024-09-02",{"date":280,"type":37},"2024-09-05",{"date":282,"type":37},"2022-01-01",{"date":284,"type":21},"2024-12-31",{"name":43,"class":44},""]